Adaptive Biotechnologies (ADPT) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Adaptive Biotechnologies is set to release its Q2 2025 earnings on August 5th, with analysts anticipating a loss of ($0.24) per share and revenue of $49.40 million.
• In its previous quarter, the company reported a loss of ($0.20) per share, exceeding estimates, and achieved a revenue increase of 25.2% year-over-year.
• Institutional investors hold a significant stake in the company, with 99.17% of the stock owned by them and various firms actively adjusting their holdings in recent months.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) is anticipated to announce its Q2 2025 earnings results after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $49.40 million for the quarter.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.08. Adaptive Biotechnologies had a negative net margin of 74.84% and a negative return on equity of 62.79%. The business had revenue of $52.44 million for the quarter, compared to analyst estimates of $42.13 million. During the same period in the previous year, the company earned ($0.33) earnings per share. The business's revenue for the quarter was up 25.2% on a year-over-year basis. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Price Performance

NASDAQ ADPT traded up $0.09 on Friday, hitting $10.33. The stock had a trading volume of 1,709,402 shares, compared to its average volume of 1,544,923. The business's fifty day moving average price is $10.67 and its 200 day moving average price is $8.93. Adaptive Biotechnologies has a 52-week low of $3.85 and a 52-week high of $12.43. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -10.76 and a beta of 1.92.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ADPT shares. Morgan Stanley lifted their price target on shares of Adaptive Biotechnologies from $7.00 to $9.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Piper Sandler reissued an "overweight" rating and set a $13.00 price objective (up from $11.00) on shares of Adaptive Biotechnologies in a report on Tuesday, May 6th. The Goldman Sachs Group boosted their price objective on shares of Adaptive Biotechnologies from $9.00 to $10.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Finally, Craig Hallum began coverage on shares of Adaptive Biotechnologies in a report on Wednesday, June 18th. They set a "buy" rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $10.57.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADPT. AQR Capital Management LLC lifted its position in Adaptive Biotechnologies by 45.8% during the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company's stock valued at $2,265,000 after purchasing an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company's stock worth $511,000 after acquiring an additional 2,914 shares during the period. Finally, Caxton Associates LLP acquired a new position in shares of Adaptive Biotechnologies in the first quarter worth about $93,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.